SCHEMBL5349780

SCHEMBL5349780

CN(CCc1cccnc1)Cc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.67
CHRNB2 P17787 2/20 0.62
CHRNA4 P43681 2/20 0.62
CARM1 Q86X55 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
PRMT8 Q9NR22 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
TDP1 Q9NUW8 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
OPRM1 P35372 1/20 0.47
OPRL1 P41146 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 1/20 0.47
TSHR P16473 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069056 0.90 SIGMAR1 (0.61) CHRNA7CHRNB2CHRNA4CARM1PRMT6
SCHEMBL6585395 0.84 CHRNB2 (0.63) CHRNA7CHRNB2CHRNA4SIGMAR1TDP1
SCHEMBL8402960 0.82 SIGMAR1 (0.71) CARM1PRMT6PRMT8SIGMAR1TSHR
SCHEMBL8363021 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4TDP1L3MBTL1
SCHEMBL30093157 0.80 CHRNB2 (0.79) CHRNA7CHRNB2CHRNA4TDP1L3MBTL1
SCHEMBL30772178 0.80 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4TDP1L3MBTL1
SCHEMBL10028665 0.80 CHRNB2 (0.85) CHRNA7CHRNB2CHRNA4TDP1L3MBTL1
SCHEMBL16627431 0.79 CHRNB2 (0.77) CHRNA7CHRNB2CHRNA4TDP1L3MBTL1
SCHEMBL6538284 0.78 SIGMAR1 (0.67) CARM1PRMT6PRMT8SIGMAR1TSHR
SCHEMBL16211015 0.78 CHRNA7 (0.54) CHRNA7CHRNB2CHRNA4L3MBTL1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 CHRNA7 2377/4885CHRNB2 3066/4885CHRNA4 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.